Probing polynuclear platinum biomolecule interactions

探索多核铂生物分子相互作用

• 批准号: DP1095383
• 负责人: Prof Susan Berners-Price
• 金额: $ 18.84万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP1095383
• 关键词: Probing; polynuclear; platinum; biomolecule; interactions

Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students.

癌症影响四分之一的澳大利亚人，50%的癌症患者接受顺铂治疗。BBR 3464是一种新型的铂类抗癌药物，在临床试验中显示出了希望，包括对顺铂治疗无反应的癌症的结果。目前正在开发的第二代类似物可能具有显著的优势。与这些新药发明者的国际合作使澳大利亚的研究处于临床开发的最前沿。 在设计改进的抗癌药物中，有可能从新策略中产生新的IP。该项目建立了强大的国际联系，并为澳大利亚博士生提供国际培训。